{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:48:12Z","timestamp":1761896892798,"version":"3.40.5"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","lrjournal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1016\/j.leukres.2018.09.018","type":"journal-article","created":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T21:52:54Z","timestamp":1538430774000},"page":"75-79","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Safety and efficacy of switching from branded to generic imatinib in chronic phase chronic myeloid leukemia patients treated in Italy"],"prefix":"10.1016","volume":"74","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0716-1686","authenticated-orcid":false,"given":"Massimiliano","family":"Bonifacio","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luigi","family":"Scaffidi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gianni","family":"Binotto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Cristina","family":"Miggiano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Danini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Minotto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Davide","family":"Griguolo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luciana","family":"Marin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca","family":"Frison","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabio","family":"D\u2019Amore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Basso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Sartori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martina","family":"Tinelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuela","family":"Stulle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefania","family":"Fortuna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela","family":"Bonalumi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Bertoldero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ercole","family":"De Biasi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Ruggeri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gianpietro","family":"Semenzato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renato","family":"Fanin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Pizzolo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mauro","family":"Krampera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario","family":"Tiribelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.leukres.2018.09.018_bib0005","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1038\/leu.2016.246","article-title":"Treatment and outcome of 2904 CML patients from the EUTOS population-based registry","volume":"31","author":"Hoffmann","year":"2017","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.leukres.2018.09.018_bib0010","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1056\/NEJMoa1609324","article-title":"Long-term outcomes of imatinib treatment for chronic myeloid leukemia","volume":"376","author":"Hochhaus","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"24","key":"10.1016\/j.leukres.2018.09.018_bib0015","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1200\/JCO.2015.66.2866","article-title":"Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population","volume":"34","author":"Bower","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"22","key":"10.1016\/j.leukres.2018.09.018_bib0020","doi-asserted-by":"crossref","first-page":"4439","DOI":"10.1182\/blood-2013-03-490003","article-title":"The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts","volume":"121","author":"Experts in Chronic Myeloid Leukemia","year":"2013","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.leukres.2018.09.018_bib0025","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1038\/leu.2016.220","article-title":"Chronic myeloid leukemia patients call for quality and consistency when generics are introduced to treat their cancer","volume":"30","author":"Geissler","year":"2016","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.leukres.2018.09.018_bib0030","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.3109\/10428194.2014.904508","article-title":"Prospective single-center study of chronic myeloid leukemia in chronic phase: switching from branded imatinib to a copy drug and back","volume":"55","author":"Alwan","year":"2014","journal-title":"Leuk. Lymphoma"},{"issue":"12","key":"10.1016\/j.leukres.2018.09.018_bib0035","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.3109\/10428194.2014.893302","article-title":"Deleterious effects of non-branded versions of imatinib used for the treatment of patients with chronic myeloid leukemia in chronic phase: a case series on an escalating issue impacting patient safety","volume":"55","author":"Saavedra","year":"2014","journal-title":"Leuk. Lymphoma"},{"issue":"4","key":"10.1016\/j.leukres.2018.09.018_bib0040","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.clml.2017.02.001","article-title":"The efficacy of generic imatinib as first- and second-line therapy: 3-year follow-up of patients with chronic myeloid leukemia","volume":"17","author":"Islamagic","year":"2017","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"7","key":"10.1016\/j.leukres.2018.09.018_bib0045","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.clml.2017.05.006","article-title":"Generic imatinib in chronic myeloid leukemia: survival of the cheapest","volume":"17","author":"Danthala","year":"2017","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"1","key":"10.1016\/j.leukres.2018.09.018_bib0050","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/bjh.12937","article-title":"First line treatment of chronic phase chronic myeloid leukaemia patients with the generic formulations of imatinib mesylate","volume":"167","author":"Eskazan","year":"2014","journal-title":"Br. J. Haematol."},{"issue":"12","key":"10.1016\/j.leukres.2018.09.018_bib0055","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.1016\/j.clml.2017.08.001","article-title":"Generic imatinib therapy among Jordanians: an observational assessment of efficacy and safety in routine clinical practice","volume":"17","author":"Awidi","year":"2017","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"7","key":"10.1016\/j.leukres.2018.09.018_bib0060","doi-asserted-by":"crossref","first-page":"e125","DOI":"10.1002\/ajh.24748","article-title":"A multicenter prospective study on efficacy and safety of imatinib generics: a report from Polish Adult Leukemia Group imatinib generics registry","volume":"92","author":"Sacha","year":"2017","journal-title":"Am. J. Hematol."},{"issue":"12","key":"10.1016\/j.leukres.2018.09.018_bib0065","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.clml.2017.07.255","article-title":"Outcomes of chronic myeloid leukemia patients with early molecular response at 3 and 6 months: a comparative analysis of generic imatinib and Glivec","volume":"17","author":"Eskazan","year":"2017","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"2","key":"10.1016\/j.leukres.2018.09.018_bib0070","doi-asserted-by":"crossref","first-page":"151","DOI":"10.31768\/2312-8852.2017.39(2):151-154","article-title":"Generic imatinib in the treatment of chronic myeloid leukemia: two years\u2019 experience in Latvia","volume":"39","author":"Lejniece","year":"2017","journal-title":"Exp. Oncol."},{"issue":"6","key":"10.1016\/j.leukres.2018.09.018_bib0075","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013","volume":"122","author":"Baccarani","year":"2013","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.leukres.2018.09.018_bib0080","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1038\/leu.2015.29","article-title":"Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia","volume":"29","author":"Cross","year":"2015","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.leukres.2018.09.018_bib0085","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1038\/leu.2015.152","article-title":"Long-term outcomes of chronic myeloid leukemia patients treated frontline with imatinib","volume":"29","author":"Castagnetti","year":"2015","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.leukres.2018.09.018_bib0090","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1002\/ajh.24774","article-title":"The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib","volume":"92","author":"Castagnetti","year":"2017","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.leukres.2018.09.018_bib0095","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.597.597","article-title":"Predictive factors of stable deep molecular response in chronic myeloid leukemia patients treated with imatinib standard dose: a study from the Gruppo Triveneto LMC","volume":"126","author":"Bonifacio","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2018.09.018_bib0100","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.critrevonc.2016.05.009","article-title":"Early switch in tyrosine kinase inhibitor therapy for patients with chronic myeloid leukemia: an emerging clinical question","volume":"103","author":"Sweet","year":"2016","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"17","key":"10.1016\/j.leukres.2018.09.018_bib0105","doi-asserted-by":"crossref","first-page":"4554","DOI":"10.1182\/blood-2011-04-347575","article-title":"Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population","volume":"118","author":"Efficace","year":"2011","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.leukres.2018.09.018_bib0110","doi-asserted-by":"crossref","DOI":"10.1111\/ecc.12423","article-title":"The impact of new generic formulations of imatinib mesylate on general quality of life in chronic phase chronic myeloid leukaemia patients","volume":"26","author":"Uyanik","year":"2017","journal-title":"Eur. J. Cancer Care (Engl.)"},{"issue":"4","key":"10.1016\/j.leukres.2018.09.018_bib0115","doi-asserted-by":"crossref","first-page":"788","DOI":"10.3324\/haematol.2013.093724","article-title":"Patient- versus physician-reporting of symptoms and health status in chronic myeloid leukemia","volume":"99","author":"Efficace","year":"2014","journal-title":"Haematologica"},{"issue":"24","key":"10.1016\/j.leukres.2018.09.018_bib0120","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia","volume":"362","author":"Saglio","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"24","key":"10.1016\/j.leukres.2018.09.018_bib0125","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"362","author":"Kantarjian","year":"2010","journal-title":"N. Engl. J. Med."}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212618302236?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212618302236?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,10,25]],"date-time":"2019-10-25T02:16:56Z","timestamp":1571969816000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212618302236"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":25,"alternative-id":["S0145212618302236"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2018.09.018","relation":{},"ISSN":["0145-2126"],"issn-type":[{"type":"print","value":"0145-2126"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and efficacy of switching from branded to generic imatinib in chronic phase chronic myeloid leukemia patients treated in Italy","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2018.09.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}